


**Cell Reports Medicine, Volume 5**

**Supplemental information**


**mRNA-delivery of IDO1 suppresses**

**T cell-mediated autoimmunity**


**Laurie L. Kenney, Rebecca Suet-Yan Chiu, Michelle N. Dutra, Alexandra Wactor, Chris Honan, Lukas Shelerud, Joshua J. Corrigan, Kelly Yu, Joseph D. Ferrari, Kate L. Jeffrey, Eric Huang, and Paul L. Stein**




**Supplemental Figure 1. Engineered IDO1 induces dose-dependent changes in serum TRP and KYN in mouse and rat. Related to Fig 2.** (A–C) Naïve C57BL/6 mice were injected i.v. with 0.5, 0.25, or 0.125 mg/kg of LNP A-formulated mRNA. Serum (A) KYN, (B) TRP, and (C) KYN:TRP ratios were determined at 72 h by ELISA. Significance was determined by one-way ANOVA compared with Dead SRC.IDO controls with secondary Sidak’s multiple comparisons test. \*\*\*\* $p < 0.0001$ . (D–F) Naïve Sprague Dawley rats were injected i.v. with 0.5, 0.25, 0.125 or 0.0625 mg/kg of LNP A-formulated mRNA and plasma (D) KYN, (E) TRP, and (F) KYN:TRP ratios were determined at 72 h by ELISA. Data are individual rats and medians of  $n=3-5$  animals/group and representative of 2 similar experiments. Significance was determined by one-way ANOVA compared with Dead SRC.IDO controls with secondary Dunnett’s multiple comparisons test. \* $p < 0.05$ , \*\* $p < 0.005$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$ .



**Supplemental Figure 2. mRNA-delivered anchored IDO1 is bioactive in NHP. Related to Fig 2. (A, B)** NHP were infused over 60 mins along with 0.3 or 1.0 mg/kg of LNP B-formulated mRNA. Blood samples were obtained at 6, 12, 24, 96, 168, 240, and 312 h post-injection. (A) KYN and (B) TRP were measured in the serum by ELISA. N=3 NHP/group. Data are mean and s.e.m. and are representative of similar experiments. Significance was determined by two-way ANOVA compared with Dead SRC.IDO controls using Dunnett's multiple comparisons tests. \* $p < 0.05$ , \*\* $p < 0.005$ , \*\*\* $p < 0.0005$ , \*\*\*\* $p < 0.0001$ . (C & D) (C) KYN levels at 6 h and (D) TRP levels at 24 h post-injection determined by ELISA from serum. N=5–11 NHP/group. Data are individual NHP and median and are pooled from 3 similar experiments. Significance was determined by one-way ANOVA compared with Dead SRC.IDO controls using Dunnett's multiple comparisons tests. \*\* $p < 0.005$ , \*\*\* $p < 0.0005$ .



**Supplemental Figure 3. In vivo function is sustained with repeat dosing of SRC.IDO. Related to Fig 2.** Naïve C57BL/6 mice were injected i.v. with 0.5 mg/kg of LNP A-formulated mRNA every 7 days for 5 weeks. Serum (A) KYN and (B) TRP were determined at 24 h post each administration by ELISA. Significance was determined by two-way ANOVA with Tukey's multiple comparisons test. \*\*\*\* $p < 0.0001$ . Data are individual mice and medians of 3-5 mice/groups and representative of 2 similar experiments.



**Supplemental Figure 4. Protein expression and changes in metabolite levels in SRC.IDO\_miR122ts- and SRC.IDO\_miR142ts-treated mice. Related to Fig 6.** Naïve C57BL/6 mice were injected i.v. with 0.5 mg/kg of LNP A-formulated mRNA. Human IDO1 protein expression in (A) spleen and (B) liver lysates was determined at 24 h by ELISA. Significance was determined by one-way ANOVA compared to SRC.IDO with Dunnett's multiple comparisons. \*\* $p < 0.005$ , \*\*\* $p < 0.0005$ , \*\*\*\* $p < 0.0001$ . Serum (C) KYN, (D) TRP and (E) KYN:TRP ratio were determined at 24 h by ELISA. Significance was determined by one-way ANOVA with Tukey's multiple comparisons. \* $p < 0.05$ , \*\* $p < 0.005$ , \*\*\*\* $p < 0.0001$ . Data are individual mice and medians of 5 mice/groups and representative of 4 similar experiments.

**Supplemental Table 2. Lists the antibodies used for the flowcytometry analysis used for aGVHD studies, related to the Flowcytometry for aGVHD section of the STAR Methods.**

Color	Antigen	Clone	Company	Order number	Dilution
APC-eFluor780	Viability	n/a	Invitrogen	65-0865-14	1:5000
BUV805	CD3	145-2C11	BD biosciences	749276	1:400
BV785	CD4	GK1.5	Biolegend	100453	1:400
BUV737	CD8	53-6.7	BD Biosciences	612759	1:400
AF700	CD19	6D5	Biolegend	115528	1:800
PE	H2-Kd	SF1-1.1.1	Invitrogen	12-5957-82	1:400
BV421	H2-Kb	AF6-88.5	Biolegend	116525	1:400
AF647	FoxP3	150D	Biolegend	320014	1:200
BV605	Ki67	16A8	Biolegend	652413	1:200
FITC	Caspase-3	C92-605	BD Biosciences	559341	1:500